First-in-human study (FIH) of FS222, a next-generation tetravalent PD-L1/CD137 bispecific antibody: Safety, pharmacodynamics (PD), and antitumor activity in patients (pts) with advanced solid tumors including PD-1 refractory melanoma

被引：0

作者：

Garralda, Elena

Oberoi, Arjun

de Velasco, Guillermo

Victoria, Ivan

Pesantez, David

Eguren Santamaria, Inaki

Moreno, Victor

Boni, Valentina

Cervantes, Andres

Gambardella, Valentina

Ciuleanu, Tudor-Eliade

Bergamino Sirven, Milana

Rodriguez-Abreu, Delvys

Alonso, Guzman

Minea Gales, Laurentia

Jones, Daniel

Patki, Abhay

Ataman, Ozlem

Melero Bermejo, Ignacio

机构：

[1] Vall dHebron Univ Hosp HUVH, Barcelona, Spain

[2] Vall Hebron Inst Oncol VHIO, Barcelona, Spain

[3] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain

[4] Hosp Clin Barcelona, Barcelona, Spain

[5] Hosp Clin Barcelona, Barcelona, Spain

[6] Clin Univ Navarra, Pamplona, Spain

[7] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain

[8] Univ Hosp Quiron Salud, NEXT Oncol, Madrid, Spain

[9] Hosp Clin Univ Valencia, Valencia, Spain

[10] Inst Oncol Prof Dr Ion Chiricuta, Cluj Napoca, Romania

[11] Univ Med & Pharm Iuliu Hatieganu, Cluj Napoca, Romania

[12] H U Germans Trias & Pujol, ICO Badalona, Barcelona, Spain

[13] Complejo Hosp Univ Insular Materno Infant, Las Palmas Gran Canaria, Spain

[14] Hosp Quironsalud, NEXT Oncol, Barcelona, Spain

[15] Carol Davila Univ Med & Pharm, Bucharest, Romania

[16] InvoX Pharma Ltd, London, England

[17] Clin Univ Navarra, Pamplona, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2505

引用

页数：1

共 50 条

[41] A first-in-human (FIH) dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous BAL101553, a novel microtubule inhibitor, in adult patients with advanced solid tumors.
Calvert, Alan Hilary
Gonzalez, Michael
Ganguli, Sushila
Ng, Matthew
Benafif, Sarah
Capelan, Marta
Goldstein, Robert
Shah, Krunal
Jarvis, Claire
Flynn, Michael
Forster, Martin
Anderson, Stephanie
Schmitt-Hoffman, Anne
Lane, Heidi
Engelhardt, Marc
Hannah, Alison L.
Tzankov, Alexandar
Bachmann, Felix
Molife, L. Rhoda
Kristeleit, Rebecca
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[42] Phase I study of IBI322 (anti-CD47/PD-L1 bispecific antibody) monotherapy therapy in patients with advanced solid tumors in China.
Wang, Jie
Sun, Yuping
Chu, Qian
Duan, Jianchun
Wan, Rui
Wang, Zhijie
Zhao, Jun
Li, Haoyuan
Guo, Yingmei
Chen, Yuling
Wang, Yan
CANCER RESEARCH, 2022, 82 (12)
[43] Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study.
Varga, Andrea
Piha-Paul, Sarina Anne
Ott, Patrick Alexander
Mehnert, Janice M.
Berton-Rigaud, Dominique
Johnson, Elizabeth A.
Cheng, Jonathan D.
Yuan, Sammy
Rubin, Eric H.
Matei, Daniela E.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[44] Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Muik, Alexander
Garralda, Elena
Altintas, Isil
Gieseke, Friederike
Geva, Ravit
Ben-Ami, Eytan
Maurice-Dror, Corinne
Calvo, Emiliano
LoRusso, Patricia M.
Alonso, Guzman
Rodriguez-Ruiz, Maria E.
Schoedel, Kristina B.
Blum, Jordan M.
Sanger, Bianca
Salcedo, Theodora W.
Burm, Saskia M.
Stanganello, Eliana
Verzijl, Dennis
Vascotto, Fulvia
Sette, Angelica
Quinkhardt, Juliane
Plantinga, Theo S.
Toker, Aras
van den Brink, Edward N.
Fereshteh, Mark
Diken, Mustafa
Satijn, David
Kreiter, Sebastian
Breij, Esther C. W.
Bajaj, Gaurav
Lagkadinou, Eleni
Sasser, Kate
Tureci, Ozlem
Forssmann, Ulf
Ahmadi, Tahamtan
Sahin, Ugur
Jure-Kunkel, Maria
Melero, Ignacio
CANCER DISCOVERY, 2022, 12 (05) : 1248 - 1265
[45] A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)
Lakhani, N.
Cosman, R.
Banerji, U.
Rasco, D.
Tomaszewska-Kiecana, M.
Garralda, E.
Kornacki, D.
Li, J.
Tian, C.
Bourayou, N.
Powderly, J.
ESMO OPEN, 2024, 9 (04)
[46] Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors
Kyriakos P. Papadopoulos
Nehal Lakhani
Gerald S. Falchook
Gosia Riley
Johan Baeck
Karen S. Brown
Gilad Gordon
Lidya Le
Judy S. Wang
Cancer Immunology, Immunotherapy, 2021, 70 : 763 - 772
[47] Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors
Papadopoulos, Kyriakos P.
Lakhani, Nehal
Falchook, Gerald S.
Riley, Gosia
Baeck, Johan
Brown, Karen S.
Gordon, Gilad
Le, Lidya
Wang, Judy S.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (03) : 763 - 772
[48] Pharmacokinetics and pharmacodynamics of MEDI4736, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal antibody, in patients with advanced solid tumors.
Song, Xuyang
Pak, Min
Chavez, Carlos
Liang, Meina
Lu, Hong
Schwickart, Martin
Blake-Haskins, John A.
Robbins, Paul B.
Jin, Xiaoping
Gupta, Ashok Kumar
Roskos, Lorin
Narwal, Rajesh
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[49] First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors
Cooper, A.
Andelkovic, V.
Wilkinson, K.
Ganju, V.
Lundy, J.
Hong, M.
Airey, S.
Meng, L. L.
Shen, B.
Li, H.
Yao, L.
Zhang, M.
Coward, J.
ANNALS OF ONCOLOGY, 2023, 34 : S487 - S487
[50] Final results of the first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in combination with nivolumab in subjects with solid tumors relapsed/refractory to prior anti-PD1/PD-L1 treatment
Melero, I.
De Miguel, M. J.
Casal, G. Alonso
Goebeler, M-E.
Ramelyte, E.
Calvo, E.
Garralda, E.
Dummer, R.
Rodriguez-Ruiz, M. E.
Sayehli, C. M.
Sanmamed, M. F.
Ramon, J. L.
Bardaji, M. J. Lostes
Gromke, T.
Schuler, M. H. H.
Fettes, P.
Klar, K.
Schuberth-Wagner, C.
Wischhusen, J.
Leo, E.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S876 - S876

← 1 2 3 4 5 →